Drugs / Bacillus Calmette-Guerin
Bacillus Calmette-Guerin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01119521 | Oct 2010 → Jul 2013 | tuberculosis | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bacillus Calmette-Guerin | “Bacillus Calmette-Guérin (BCG) Revaccination of Adults with Latent Mycobacterium tuberculosis Infection Induces Long-Lived BCG-Reactive NK Cell Responses.” PMID 27412415 ↗ Jul 20161“Intradermal Bacillus Calmette-Guerin (BCG) live-attenuated vaccine prepared using the Danish 1331 BCG substrain” NCT01119521 ↗ |
| Known as | BCG | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01119521 ↗ |
| Known as | BCG Vaccine SSI | “intradermal revaccination with BCG Vaccine SSI (Statens Serum Institut, Copenhagen)” PMID 24814553 ↗ May 2014 |
| Modality | Vaccine | “Intradermal Bacillus Calmette-Guerin (BCG) live-attenuated vaccine prepared using the Danish 1331 BCG substrain” NCT01119521 ↗ |